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Abstract: Macromolecules present a remarkable potential as
future therapeutics. However, their translation into clinical
practice has been hampered by an inherently low bioavaila-
bility. Cell-penetrating peptides (CPP) have been recently
shown to signiﬁcantly improve on the bioavailability of mac-
romolecules. Yet, the high cost associated with development
and production of these peptides is a major factor hindering
their rapid deployment beyond the laboratory. Here, we
describe a facile and robust methodology for efﬁcient and
large-scale production of low-molecular-weight protamine—a
potent CPP of great clinical potential. Our methodology is
based on the immobilization of thermolysin, an enzyme
catalyzing digestion of native protamine, on chemically
surface-modiﬁed gels produced by silica sol–gel chemistry.
Thermolysin was immobilized at extremely high matrix loading
of 733 mg/g matrix and exhibited good thermal and pH
stability, indicating robustness with respect to processing
conditions. The mechanical properties of the silica matrix
further allowed utilization of the immobilized thermolysin in
both batch and packed-bed reactor systems to produce the
LMWP peptide in high yields. Results presented here are of
high signiﬁcance as this efﬁcient and cost-effective production
of high purity LMWP could enable clinical translation of many
potential macromolecular drugs. VC 2011 Wiley Periodicals, Inc.
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INTRODUCTION
An increased understanding of biological pathways and
unraveling of the human genome over the past decade have
elucidated the many factors that affect disease progression.
This new knowledge has in turn highlighted many new
potential targets for the treatment of disease. Although
small molecule drugs have been utilized for centuries to
treat various ailments, their lack of speciﬁcity often leads to
serious side effects. Biomacromolecules (e.g., proteins and
oligonucleotides), on the other hand, can offer unmatched
target speciﬁcity and selectivity. The exquisite speciﬁcity of
oligonucleotides, for example, has been shown,1,2 with the
potential ability to even discriminate between mRNAs
differing in only a single base pair.3 Clinical use of macromo-
lecular drugs, however, is hindered by several barriers,
including: (1) their limited bioavailability, (2) high produc-
tion costs, and (3) instability in biological ﬂuids. Addition-
ally, because the majority of these molecules cannot pene-
trate the cellular membrane, additional hurdles exist for
macromolecules that target intracellular components.4
The bioavailability of macromolecular therapeutics has
been enhanced through conjugation with the recently discov-
ered class of cell-penetrating peptides (CPP).5 Although the
mechanism is still unclear, these CPPs have demonstrated an
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ability to ferry large proteins (e.g., b-galactosidase) into
many different cell types and even facilitate crossing of the
blood-brain barrier.6 Additionally, CPPs have been shown to
enhance the oral bioavailability of insulin,7 increase transfec-
tion efﬁciency of siRNAs,8 and even improve the intracellular
uptake of nanoparticulate drug carriers.9 Although the
potential for these peptides to enhance delivery of macromo-
lecular drugs is tremendous, this has yet to be realized in
clinical practice.10,11 It has been suggested that technical
challenges, risk mitigation, and development costs could all
be factors hindering the overall development of CPP-drug
conjugates.12,13
CPPs are typically produced by recombinant or solid-
phase synthesis methods, and the raw material cost and the
extensive puriﬁcation requirements make the cost prohibi-
tively high for large-scale utilization. For example, the cur-
rent commercial price for milligram quantities of a peptide
of >98% purity (greater purity improves chances of regula-
tory approval) is in the range of US$25–$50 per amino acid
residue. This puts the CPP peptide on the same scale, or
above, in magnitude of cost as many of the macromolecular
drugs themselves. Development of an inexpensive, high-pu-
rity CPP, which exhibits a proven safety proﬁle, could be the
necessary impetus for carrying many of the promising mac-
romolecular drugs into clinical translation.13
The development of low-molecular-weight protamine
(LMWP), from the clinically utilized drug protamine, has
been previously described.14 Although initially developed
for heparin reversal,15,16 the structural similarities of LMWP
with HIV-TAT prompted evaluation of its cell-penetrating
properties. The resulting studies showed that LMWP
enhanced intracellular delivery of DNA,17,18 siRNA,19 thera-
peutic proteins,20,21 drug-conjugated polymers,22,23 and
even nanoparticles.24 LMWPs potent cell-penetrating prop-
erties, combined with its proven nontoxic and nonimmuno-
genic proﬁle,25–27 exceeding that of the FDA-approved prot-
amine, make it an attractive candidate for clinical use in
improving macromolecular drug efﬁcacy. We here further
demonstrate that the LMWP peptide can be efﬁciently pro-
duced on a large scale, at high purity, and at relatively low
costs—transforming it from just another interesting labora-
tory compound into one that is commercially viable for
eventual clinical translation.
Production of LMWP is achieved by thermolysin-catalyzed
digestion of native protamine. Thermolysin (EC 3.4.24.27) is a
bacterial, zinc-dependent neutral metalloprotease that acts as
a catalyst for the hydrolysis/synthesis of peptide bonds, with
high speciﬁcity for amino acids containing bulky, hydrophobic
side chains. Thermolysin-mediated digestion of protamine
results in the formation of several peptides of varying lengths
and amino acid compositions, which have been labeled
sequentially from TDSP1 to TDSP5 based on their increasing
heparin binding strength.28 TDSP5, the largest fragment with
an amino acid sequence of VSRRRRRRGGRRRR, is the peptide
of interest here and any reference to LMWP will henceforth
indicate the TDSP5 fragment.
Previously, we reported the immobilization of invertase
on amino-chemically surface-modiﬁed gel (N-CSMG) pro-
duced by silica sol–gel chemistry.29 In that work, it was
shown that an extremely high enzyme loading, 723 mg in-
vertase/g matrix, could be achieved with complete retention
of the enzyme’s catalytic efﬁciency (Vmax/Km). Because
N-CSMG displayed considerable promise as an immobiliza-
tion matrix, we turned our efforts to the immobilization of
thermolysin for the production of LMWP. The immobilized
thermolysin is characterized by determination of the pH
and temperature-dependent activity proﬁles in comparison
with those of free thermolysin. We then examine the stabil-
ity of the immobilized thermolysin in both batch and
packed-bed reactor (PBR) systems and demonstrate its
potential for large-scale peptide production.
MATERIALS AND METHODS
Materials
Thermolysin (Type X, lyophilized powder, 50–100 units/mg
protein) from Bacillus thermoproteolyticus rokko, glutaralde-
hyde (25 wt % in water), protamine sulfate salt from salmon
(Grade X), trichloroacetic acid (98% pure), 3-aminopropyl-
triethoxysilane (APTES), and azocasein were purchased from
Sigma–Aldrich (St. Louis, MO) and used as supplied. Sodium
silicate (N-type) was purchased from PQ Corporation (Valley
Forge, PA). All other reagents were of analytical grade, and
water was distilled and deionized. Hi-Trap Heparin columns
were purchased from GE Life Sciences (Piscataway, NJ).
Methods
Synthesis of N-CSMG and glutaraldehyde-activated silica
gel. The sol–gel process used for production of N-CSMG
and glutaraldehyde-activated silica gel (GA-N-CSMG) were as
previously described29 and is depicted in Scheme 1. Brieﬂy,
silicic acid (H2SiO3) was produced from sodium silicate
(Na2SiO3) using an ion exchange process. The silicic acid
was then mixed with APTES, in the presence of ethanol as
cosolvent, to produce amino-functionalized, monolithic gels
(N-CSMG). The N-CSMG gel was then mechanically ground
and successively washed with ethanol and then ddH2O to
remove any unreacted monomers. The washed N-CSMG was
then activated with 0.5 wt % glutaraldehyde (GA), a homo-
bifunctional crosslinker, to produce GA-N-CSMG. The result-
ing GA-activated gel was separated by ﬁlter paper
and washed several times with ddH2O to remove any excess
SCHEME 1. Procedure for preparation of amino-chemically surface
modiﬁed gel (N-CSMG) and glutaraldehyde-activated N-CSMG (GA-N-
CSMG). dd ¼ double-distilled.
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GA. The washed gel was stored at 4C, for up to 1 month,
until used.
Immobilization of thermolysin on GA-N-CSMG. To immobi-
lize thermolysin, 500 mg of GA-N-CSMG were weighed into
a 50-mL conical vial. Twenty milliliters of 2 g/L thermoly-
sin, in 50 mM phosphate buffer at pH 7.0, were introduced
to the vial and the suspension stirred at 4C for 12 h. The
suspension was then centrifuged at 10,000g for 10 min
and the supernatant, containing free thermolysin, removed.
The thermolysin-immobilized gel was washed three times
with 20 mL of 100 mM phosphate buffer (pH 7.0) and cen-
trifuged between each wash. Protein content in the superna-
tant was followed using the Bradford assay,30 and three
washes were found to be adequate for removal of all free
enzyme. Measured concentrations were used to determine
enzyme loading on the GA-N-CSMG gels by mass balance.
The immobilized thermolysin was stored in 20 mM
phosphate buffer (pH 7.0) at 4C until use.
Measurement of thermolysin activity. Thermolysin activity
was measured colorimetrically with azocasein as substrate.
The enzyme, free or immobilized, was incubated with 4 mL
of 0.5 wt % azocasein solution. Proteolysis of the casein
releases a soluble dye into solution, which can be detected
by measuring absorbance at 440 nm. The reaction was
stopped by addition of 500 lL of 15% trichloroacetic acid to
a 1 mL aliquot of the reaction solution, which induces precip-
itation of any undigested azocasein. The precipitate was then
removed from solution by centrifugation at 12,000g for
5 min. Enzymatic activity is proportional to the dye remain-
ing in solution. One unit of thermolysin activity was taken
to equal the amount of enzyme producing an increase of
0.1 absorbance units/min at 440 nm. All activity tests were
conducted in triplicate and are reported as mean 6 S.D.
Effect of pH on immobilized thermolysin activity. The pH-
dependant activity proﬁles of both the immobilized- and
free thermolysin were determined using the procedure
described above, at 37C in 50 mM buffered solutions. An
acetate buffer was used for pH 5.0, phosphate buffer for pH
6.0 and 6.5, tris(hydroxymethyl)aminomethane (TRIS)/HCl
was used for pH 7.0, 7.5, and 8.0, and TRIS/NaOH was used
for pH 9.0.
Effect of temperature on immobilized thermolysin activity.
The effect of temperature on both free- and immobilized
thermolysin activity was determined by measuring the
hydrolysis of azocasein at temperatures ranging from 25 to
85C. Enzymatic activity was measured as described above,
using a 0.5 wt % azocasein solution buffered with 50 mM
TRIS/HCl (pH 7.0).
Batch production of LMWP by immobilized thermolysin.
Immobilized thermolysin (50 mg matrix) was introduced to
100 mL of a magnetically stirred, thermostated solution
consisting of 10 mg/mL protamine, 2 mM CaCl2, and 50 mM
Tris/HCl buffer (pH 7.4). Protamine hydrolysis was allowed
to proceed for speciﬁed time intervals and the reaction then
halted by addition of ethylenediaminetetraacetic acid, which
chelates the Ca2þ cofactor required for enzymatic activity.
After ﬁltration with a 0.22-lm syringe ﬁlter, to remove the
immobilized thermolysin, peptide fragments in a sample of
the reaction solution were analyzed by HPLC, as described
in Section ‘‘Analysis of LMWP production by HPLC.’’ Produc-
tion efﬁciency was determined by the fractional area of the
LMWP peak relative to all other peaks in the chromato-
graph. Batch stability of the immobilized thermolysin was
determined by measuring the LMWP produced in sequential
batches at reaction temperatures ranging from 35 to 55C.
Immobilized thermolysin PBR for continuous LMWP
production. The production of LMWP by immobilized
thermolysin was also analyzed in a PBR. The PBR consisted
simply of a 0.22-lm syringe ﬁlter (Fisher brand, Cat. No.
09-719A) loaded with 45 mg of silica matrix containing
33 mg of immobilized thermolysin. Protamine solution,
10 mg/mL buffered at pH 7.5 (50 mM TRIS/HCl, 2 mM
CaCl2), was introduced through the ﬁlter injection port with
a peristaltic pump at a ﬂow rate of 1 mL/min. Although the
0.22-lm membrane retained the silica gel with the immobi-
lized thermolysin, the digested protamine solution that
passed through was collected and then analyzed by HPLC.
The PBR and feed line were immersed in a 45C water bath
to maintain reaction temperature.
Analysis of LMWP production by HPLC. A HPLC gradient
system, consisting of dual Alltech Model 526 pumps (Grace,
Deerﬁeld, IL), a Linear UVIS200 detector (Grace, Deerﬁeld, IL),
and a PeakSimple Chromatography Data System Model 202
(SRI Instruments, Torrance, CA) was utilized to monitor the
peptides produced during enzymatic digestion of protamine,
as previously described.28 Brieﬂy, the various peptides were
separated by their heparin binding afﬁnity, using a 1 mL
HiTrap Heparin HP column (GE Healthcare, Piscataway, NJ).
The system was equilibrated with 50 mM TRIS/HCl (pH
7.5) before injection of test sample and the peptides eluted
with a linear NaCl gradient. Peptide fractions were moni-
tored by absorbance at 214 nm.
RESULTS AND DISCUSSIONS
Development of silica gels for high-capacity enzyme
immobilization
Enzymes are catalytic proteins that can substantially
increase reaction rates and improve product yields, while
operating under mild reaction conditions. They have, there-
fore, attracted much attention for the development of
‘‘green’’ chemistry production processes. Although the high
production efﬁciency has encouraged the integration of
enzymes in industrial processes, these efforts have been
hampered by the short half-life and relatively high cost of
enzymes. These issues could be mitigated through the
immobilization of the enzyme on a solid matrix, allowing
easy recovery and repeated use of the enzyme, which
reduces operational costs. Enzyme immobilization has also
been shown to provide the additional advantage of
ORIGINAL ARTICLE
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH A | JAN 2012 VOL 100A, ISSUE 1 213
enhanced stability under both operational and storage
conditions.31
The immobilization matrix must meet several important
speciﬁcations to achieve efﬁcient enzyme immobilization.
Mechanical and chemical stability are critical for insuring
reactor integrity during long-term operations. In addition,
large surface areas and high porosity are desirable as they,
respectively, enable high enzyme loadings and free diffusion
of substrate/product—together yielding higher production
rates and efﬁciency.32 Maintenance of porosity and surface
area can be challenging with nanoporous matrices because
of capillary stresses, which are inversely proportional to
pore radius, that can crack and collapse the porous struc-
ture. With silica gels, widely utilized as an enzyme immobi-
lization matrix, this challenge is especially pronounced.
Silica gels contain a considerable amount of silanol groups
which, while providing a valuable resource for surface modi-
ﬁcation,33,34 can undergo cocondensation reactions resulting
in an irreversible loss of porosity.35 Silanol cocondensation
also reduces the surface area available for enzyme immobili-
zation. To enable efﬁcient enzyme immobilization on a silica
gel matrix, we ﬁrst sought to develop a method for reduc-
tion of gel shrinkage. We hypothesized that the shrinkage of
gels can be minimized through modiﬁcation of the silica gel
while in its wet state, effectively occupying the silanol
groups and preventing their cross-reaction. The successful
utilization of this methodology and characterization of the
resulting enzyme immobilization matrix for high loading of
thermolysin are here described.
Synthesis of high-porosity silica gels using sol–gel chem-
istry. N-CSMG gels were produced according to the proce-
dure outlined in Section ‘‘Synthesis of N-CSMG and glutaral-
dehyde-activated silica gel.’’ SEM images of N-CSMG dried
with supercritical CO2 show that the material contains a dis-
tribution of pore sizes with the largest pores having diame-
ters of 50 nm, see Figure 1. Also seen is the rough surface
texture, which provides the high surface area for enzyme
immobilization. N-CSMG was further reacted with GA to pro-
duce GA-N-CSMG. Confocal ﬂuorescence microscope (Olym-
pus FV-500 with a HeNeG laser) imaging of the ﬂuorescent
Schiff-base, formed when GA reacts with amino groups on
the N-CSMG surface, suggested the homogenous distribution
of both the amino surface modiﬁcation and the GA
FIGURE 1. Visualization of supercritically dried N-CSMG by SEM under (A) low (154) and (B) high (60k) magniﬁcation revealed a rough sur-
face which likely contributed to the observed high-speciﬁc surface area. Closer inspection (C) reveals the porous surface with the largest of
pores having diameters of 50 nm (white scales at 50 nm intervals).
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crosslinker.36 A homogenous distribution of the reactive
groups is important to achieving uniform and maximum dis-
tribution of the immobilized enzyme.
Maximum thermolysin loading on GA-N-CSMG. Thermoly-
sin was immobilized onto GA-N-CSMG as described in above
Section ‘‘Immobilization of thermolysin on GA-N-CSMG.’’
Mass balance results indicated that 733 6 13 mg of thermo-
lysin was immobilized per gram of GA-N-CSMG. This is sig-
niﬁcantly higher than the maximum loading of 11.6 mg/g
carrier reported for GA-activated PVA cyrogel,37 27 mg/g-
polymer with a glycidyl methacrylate copolymer,38 and 36
mg/mL obtained with agarose gel.39 This exceptionally high
loading validated our hypothesis that wet-state modiﬁcation
of nanoporous gels could dramatically improve immobiliza-
tion loadings. Additonally, the high enzyme loading capacity
of the GA-N-CSMG allows for potential reactor miniaturiza-
tion and the continuous production of peptides with thera-
peutic applications, as discussed later.
Characterization of immobilized thermolysin and
optimization of conditions for peptide production
As with all proteins, enzyme conformation—which is critical
for enzymatic activity—is susceptible to changes in the
microenvironment, including both pH and temperature
effects. This is especially true for immobilized enzymes,
which can adopt varying tertiary conﬁgurations due to
interactions with the solid matrix, resulting in changes in
pH- and temperature-dependent activities compared to the
free enzyme. Measurement of enzymatic activity in condi-
tions of varying pH and temperature can not only provide
insight into the relative importance of reaction mechanisms
(e.g., activation energy and diffusion limitations) but also
enable the well-informed selection of initial conditions for
production process optimizations. The following sections
describe the characterization of immobilized thermolysin
activity as a function of both pH and temperature. Optimum
conditions derived from these results are then utilized to
measure the time-dependent production of LMWP in a
batch reactor, as well as the temperature stability of the
immobilized thermolysin.
Effect of pH on the activity of immobilized thermolysin.
Shifts in optimum pH of up to 2 units for immobilized
enzyme activities, compared to the free enzyme, can occur
depending on both enzyme and matrix properties.40 As seen
in Figure 2, however, no pH shift was observed with the
immobilization of thermolysin on GA-N-CSMG, with both the
immobilized and free thermolysin exhibiting maximum ac-
tivity at pH 7.5. This is in contrast to our previous work
with GA-N-CSMG, where a 1.0 unit shift to lower pH was
observed for immobilized invertase;29 this was attributed to
generation of a higher pH microenvironment close to the
surface by the basic, amino-functionalized matrix. Changes
in pH typically lead to breaking of ionic bonds within the
enzyme and a resulting change in tertiary structure and
enzymatic activity. It is possible that thermolysin, with its
enhanced conformational stability compared to other
enzymes,41 is more resistant to denaturing effects of pH.
Additionally, as the azocasein substrate utilized in this study
is much larger than the previously used sucrose, it is also
possible that diffusional limitations of azocasein into the
porous matrix, as the rate-limiting step, masked the effects
of pH. More detailed studies, however, are required to fully
elucidate the mechanism.
The current data, however, clearly indicate that the
activity of immobilized thermolysin is affected to a lesser
degree, compared to free thermolysin, by changes in pH
away from the optimum. Others have indicated that such
broadening of the pH proﬁle occurs due to a conservation
of the optimum pH within the matrix.42 Broadening of pH
proﬁles has also been attributed to diffusional limitations of
substrate/product through the matrix or to secondary inter-
actions between the enzyme and the matrix.43
Effect of temperature on the activity of immobilized ther-
molysin. The effect of temperature, ranging from 25 to
85C, on the activity of both free and immobilized thermoly-
sin was measured using azocasein as substrate. As seen in
Figure 3, the free enzyme showed an exponential increase
in activity up to 65C and a slower, linear increase at higher
temperatures up to 85C. The immobilized thermolysin,
on the other hand, exhibited an exponential increase in
enzymatic activity up to the maximum measured tempera-
ture of 85C.
According to the collision theory of chemical reactions,
molecules exist with a distribution of energies, and a prod-
uct is formed only when collision occurs between molecules
having energy greater than a potential energy barrier—the
activation energy (Ea). The number of molecules possessing
this energy follows a Boltzmann distribution—a relationship
used to develop the Arrhenius equation (shown here in log-
arithmic form):
FIGURE 2. Effect of pH on relative activity of free- and immobilized
thermolysin. Although no shift in optimum pH was observed, the
immobilized thermolysin retained greater activity, compared to free
thermolysin, at deviations away from the optimum of pH 7.5. Data
shown as mean 6 S.D. (n ¼ 3) relative activity, as determined for
each enzyme formulation independently.
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ln k ¼ lnA Ea
RT
(1)
where k is the rate constant, A the pre-exponential factor, Ea
is the activation energy, R the gas constant, and T is the
absolute temperature. Plotting ln k versus (1/T) yields a
straight line with a slope equal to –Ea/R and intercept of ln
A. Such analysis of the data revealed that the free thermoly-
sin followed Arrhenius kinetics at temperatures between 25
and 65C, while other factors apparently contributed to
non-Arrhenius behavior observed at higher temperatures.
The temperature-dependent activity proﬁles of enzymatic
reactions are primarily governed by: (1) the increase in
reaction rates with temperature, according to the Arrhenius
equation and (2) thermal denaturing of enzymes and its
resulting loss of activity. It, therefore, appears likely that
some free thermolysin activity is lost at temperatures above
65C because of thermal inactivation. This correlates well
with literature, which observed no variation in the crystal
structure of thermolysin at temperatures up to 65C.41 The
immobilized thermolysin, on the other hand, displayed
Arrhenius kinetics up to a temperature of 85C, suggesting
a greater thermal stability compared to the free form. It
should be pointed out that this data gives an indication of
the enzyme’s short-term stability. The optimization of a pro-
duction process, however, also requires the consideration of
long-term stability, which is discussed in following sections.
Results in Table I show the extrapolated activation ener-
gies and pre-exponential factors, determined using only
data within the Arrhenius regime, for free and immobilized
thermolysin. Free thermolysin displayed Ea and A values
of 22.5 kJ/mol and 1.06  108, respectively. The
apparent activation energy of the immobilized thermolysin
at 36.1 kJ/mol was signiﬁcantly higher than that of the free
form; the pre-exponential factor of 7.53  109 is also
increased. Higher activation energy for the immobilized
thermolysin could be attributed to conformational changes
brought upon by the immobilization or to potential steric
hindrance of the enzyme’s active site. Further studies, how-
ever, are required to determine the exact cause of this
change in the activation energy.
Kinetics of protamine digestion by immobilized thermolysin.
With the immobilized enzyme activity characterized in
terms of both the pH and temperature effects, we then
focused on the hydrolysis of protamine for the production
of LMWP. Protamine hydrolysis by immobilized thermolysin,
in a batch reactor at 40C, and the subsequent formation of
smaller peptides is shown in Figure 4. The zero time point
proﬁle shows the presence of a single peak, corresponding
to protamine, eluting at a salt concentration of 1.2M. The
appearance of several early eluting peaks and reduction of
the protamine peak are seen as the reaction is allowed to
FIGURE 3. Relative activity proﬁles for free- and immobilized thermo-
lysin as a function of reaction temperature. Trend lines for each data
set are drawn based on calculations using the Arrhenius equation,
with activation energy (Ea) and pre-exponential factor (A) obtained
by ﬁtting of data to the equation. Data shown as mean 6 S.D. (n ¼ 3)
relative activity, as determined for each enzyme formulation
independently.
TABLE I. Comparison of Activation Energy and






Free thermolysin 22.5 6 1.0 1.06  108
Immobilized 36.1 6 2.0 7.53  109
FIGURE 4. Heparin-afﬁnity elution proﬁles of protamine fragments,
digested by immobilized thermolysin, illustrating the dependence of
LMWP production on reaction time. [Color ﬁgure can be viewed in
the online issue, which is available at wileyonlinelibrary.com.]
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proceed for up to 40 min. The amino acid sequences for
each of these peaks have been determined and are reported
elsewhere.28 It can be seen that hydrolysis of protamine
occurs rapidly over the ﬁrst 5 min and is complete by
40 min. Some peaks were observed to be transient, appear-
ing early in the reaction and then disappearing as the
hydrolysis neared completion, such as the right shoulder on
the LMWP peak in the 5, 10, and 20 min chromatographs.
The size of the LMWP peak remained relatively constant at
even higher incubation times up to 1.5 h (data not shown),
indicating that the produced peptide is relatively stable to
hydrolysis by thermolysin.
Effect of temperature on LMWP production by immobi-
lized thermolysin. The long-term effect of temperature on
immobilized thermolysin activity was followed by determin-
ing the LMWP yield in serial batch reactions conducted at
temperatures in the range of 35–55C. Figure 5 displays the
LMWP production ratio obtained during 12 serial, batch
runs with immobilized thermolysin at temperatures of 35,
45, and 55C. After completion of each reaction, the gel
suspension was centrifuged to recover the immobilized
thermolysin, followed by washing with buffer solution. The
immobilized thermolysin was then reintroduced to a fresh
protamine solution and the reaction repeated.
At each of the temperatures tested, the LMWP peak is
initially about 19% of total peak area for the ﬁrst batch run
and continually increases over subsequent run cycles to a
maximum of about 29%. This maximum is reached faster at
the higher run temperatures; at 55C, this level was
achieved after only 6 runs, whereas 9 and 12 cycles were
required at reaction temperatures of 45C and 35C, respec-
tively. Close examination of all batch-to-batch peak areas
(data not shown) revealed that the increase in the LMWP
peak area, observed in subsequent batch numbers, was
accompanied with a decrease in area of the peak eluting at
ﬂow-through (ﬁrst peak observed in chromatographs of
Fig. 4), which contained non-heparin binding species. As the
enzyme preparation used in this work was not pure ther-
molysin but contained some contaminant proteins, it is pos-
sible that the presence of other proteases (e.g., trypsin)
resulted in nonspeciﬁc degradation of some LMWP. Upon
incubation at high temperature, the less thermostable pro-
teases would lose their hydrolytic activity—more rapidly at
higher temperatures, resulting in decreased LMWP degrada-
tion and improved production with increasing time (i.e.,
increasing batch number). The other, less likely, explanation
would be that the amino acid cleavage-site speciﬁcity of
thermolysin itself is altered due to possible conformation
changes occurring due to temperature effects.
Another temperature effect that was observed is a
decrease in immobilized thermolysin activity after six batch
cycles at 55C, apparent by a reduction of LMWP area from
about 29 6 1.5% to 25 6 1.0% from batch 6 to 12, respec-
tively. This reduction was accompanied with an increase in
the protamine peak area, indicating decreased hydrolysis of
the protamine substrate because of thermolysin inactivation.
Although the immobilized thermolysin displayed increasing
activity up to 85C in the short-term temperature exposure
studies previously discussed, the long-term denaturing
effects at even 55C were quite apparent and, therefore,
higher temperatures were not pursued. From these results,
it appears that 45C offers the optimum condition for pro-
duction of LMWP with the immobilized thermolysin. In fact,
no reduction in LMWP production with immobilized ther-
molysin was observed at 45C over a period of 7 days,
determined by 21 serial batch reactions (data not shown).
Continuous production of LMWP by an immobilized
thermolysin PBR
Industrial reactors can be divided into three basic groups:
the batch reactor, the continuous-stirred tank reactor, and
the plug-ﬂow reactor (PFR). A PFR reactor that is ﬁlled with
catalyst particles, or immobilized enzymes, is also called a
PBR. In a PBR, the residence time of the substrate is much
smaller than that of the enzyme, providing separation of the
enzyme and its continuous use. In addition, PBRs generally
provide greater control over production quality compared
to batch reactors, which may yield products of varying pu-
rity from one batch to the next. We, therefore, then exam-
ined the LMWP production performance of the immobilized
thermolysin in a PBR.
Because of the high enzyme loadings achieved, a very
small reactor was found sufﬁcient to achieve the required
conversion of protamine. In fact, this PBR was a simple disk
of 25-mm diameter and < 1 mm depth [see Fig. 6(A)]. Over
a period of 420 min, the production of LMWP by the PBR
increased from an initial of 20 to 23%, as determined by
the fractional peak area [Fig. 6(B)]. Subsequent serial
integration of a heparin column, for peptide puriﬁcation,
after the immobilized-thermolysin PBR did not result in any
noticeable loss of enzymatic activity even though the immo-
bilized thermolysin was repeatedly exposed to gradient
ﬂows containing up to 2M NaCl. Immobilization of thermo-
lysin on GA-N-CSMG, therefore, exhibited remarkable stabil-
ity and efﬁciency for the production of LMWP.
FIGURE 5. Effect of reaction temperature on LMWP yield. Area frac-
tion of the LMWP peak relative to the total area of all peaks was
determined as eluted by salt gradient from a heparin column. Data
shown as mean 6 S.D. (n ¼ 3).
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CONCLUSIONS
The immobilization of enzymes on functionalized silica gels
offers many advantages for use in large-scale processes,
including high loading capacity, improved stability, and
easy recovery, and reuse of expensive enzymes. However,
one of the hurdles faced by many sol–gel techniques is
gel shrinkage, which reduces the effective surface area
available for immobilization. Here, we demonstrated that
modiﬁcation of the formed sol–gel in the wet state offers
signiﬁcant advantages against shrinkage and helps to main-
tain the high surface area. The GA-N-CSMG had a measured
surface area of nearly 650 m2/g, which was homogenously
functionalized and provided a large surface for further
enzyme immobilization. Subsequent introduction of the
enzyme thermolysin yielded a high loading of 733 mg ther-
molysin/g matrix, much greater than other results reported
in literature. The immobilized enzyme displayed improved
stability over a wide pH range and at high temperatures.
Additionally, the high immobilization loading and long-term
retention of thermolysin activity allowed for efﬁcient
LMWP production with a very small reactor—enabling pro-
duction of large quantities of highly pure LMWP peptide
for currently ongoing preclinical safety and toxicological
evaluation.
Immobilization of thermolysin on GA-N-CSMG offers
great potential for large-scale peptide synthesis, and it is
currently being evaluated for pilot-plant scale production of
LMWP. The already established efﬁciency of LMWP for intra-
cellular delivery of large cargos, combined with this cost-
efﬁcient, large scale production, could potentially bring to
clinical practice many new promising macromolecular drugs.
Additionally, the immobilized enzyme reactor could also be
generally applied to the laboratory and/or commercial
production of other novel peptides.
FIGURE 6. (A) Immobilized thermolysin packed-bed reactor (PBR): Syringe ﬁlter (25-mm diameter) loaded with silica particles containing immo-
bilized thermolysin. (B) Production of LMWP with the immobilized thermolysin PBR operating at 45C. Fractional peak area was calculated as
the ratio of LMWP peak to total peak area as eluted by salt gradient from a heparin column. Data shown as mean 6 S.D. (n ¼ 3). [Color ﬁgure
can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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